Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

Last updated: November 30, 2023
Sponsor: University of Tennessee
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphoproliferative Disorders

Leukemia

Chronic Myeloid Leukemia

Treatment

Pharmacist communication

Comprehensive Medication Review

Patient-reported outcome measure

Clinical Study ID

NCT04663100
20-0839
  • Ages > 18
  • All Genders

Study Summary

The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care or community practices (Pharmacists Coordinated care Oncology Model [PCOM]).

This is a pilot study in which the investigators will examine the association between outcome measures, but the study design and sample size are insufficient to quantify the impact of OAA initiation or OAA adherence on adherence to chronic medications. This pilot study and data analyses are being done in preparation for a larger, controlled study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Receiving cancer care at Vanderbilt University Medical Center
  • Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL),chronic myeloid leukemia (CML), or multiple myeloma (MM)
  • Initiating an oral anticancer agent, either for the first time or a change fromprevious oral agent
  • Diagnosis of 2 chronic conditions, including at least one of the following: diabetes,hypertension, hyperlipidemia, congestive heart failure, depression/anxiety,gastroesophageal reflux disease, and/or chronic obstructive pulmonary disease
  • Patients taking at least two chronic medications, including at least one medicationfor one of the conditions listed above.
  • Willing and able to sign informed consent.

Exclusion

Exclusion Criteria:

  • Cannot communicate in English
  • Concurrent diagnosis of type 1 diabetes or human immunodeficiency virus

Study Design

Total Participants: 30
Treatment Group(s): 3
Primary Treatment: Pharmacist communication
Phase:
Study Start date:
February 08, 2021
Estimated Completion Date:
December 31, 2023

Connect with a study center

  • Vanderbilt University Medical Center

    Nashville, Tennessee 37232
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.